These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21506895)

  • 21. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.
    Pal SK; Vogelzang NJ
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):146-55. PubMed ID: 23598982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
    Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
    Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and future systemic treatments for renal cell carcinoma.
    Fisher R; Gore M; Larkin J
    Semin Cancer Biol; 2013 Feb; 23(1):38-45. PubMed ID: 22705280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Molecular targeted therapy for advanced renal cell carcinoma].
    Kanayama H
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing treatment for metastatic renal cell carcinoma.
    Patard JJ; Porta C; Wagstaff J; Gschwend JE
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1901-11. PubMed ID: 22117157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
    Rini BI; Flaherty K
    Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drug therapies for advanced renal cell carcinoma.
    Gore ME; Harrison ML; Montes A
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
    Appleby L; Morrissey S; Bellmunt J; Rosenberg J
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
    Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
    Flaherty KT; Puzanov I
    Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.
    Vrdoljak E; Ciuleanu T; Kharkevich G; Mardiak J; Mego M; Padrik P; Petruželka L; Purkalne G; Shparyk Y; Skrbinc B; Szczylik C; Torday L
    Expert Opin Pharmacother; 2012 Feb; 13(2):159-74. PubMed ID: 22195646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal cell cancer.
    Hutson TE; Figlin RA
    Cancer J; 2007; 13(5):282-6. PubMed ID: 17921725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel molecular targets for the therapy of renal cell carcinoma.
    Elfiky AA; Sonpavde G
    Discov Med; 2012 Jun; 13(73):461-71. PubMed ID: 22742652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential therapy in renal cell carcinoma.
    Escudier B; Goupil MG; Massard C; Fizazi K
    Cancer; 2009 May; 115(10 Suppl):2321-6. PubMed ID: 19402067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.